After treatment, the few cancer cells still present in the body are called minimal residual disease (MRD). The surviving cells may be so few that they don't cause visible symptoms or signs. They are typically undetectable by more common methods like looking at cells under a microscope or testing the blood for abnormal serum proteins. A positive MRD test result indicates that there is still illness present. Negative results indicate that no residual illness was found.
Moreover, MRD testing is also helpful in clinical trials for the latest medicines. It can demonstrate how well the treatment cures cancer without waiting months to see if it returns. This results in overall minimal residual disease market growth. The global minimal residual disease market was valued at USD 1,973.35 million in 2022 and is expected to grow to USD 7,131.61 million at a CAGR of 13.7% during the forecast period.
Major Growth Driving Factors
Top Report Findings:
Minimal Residual Disease Market Trends
Leukemia Dominates the Market
Since one American is diagnosed with leukemia every three minutes, it will rule the market. For example, the American Cancer Society evaluates that there will be roughly 20,050 new cases of acute myeloid leukemia, 60,650 new cases of leukemia overall, and 24,000 new leukemia-related deaths in 2022. Annual new cases of leukemia were 14.1 per 100,000 men and women. The yearly death rate for both men and women was 6.0 per 100,000.
Healthcare Organizations Hold the Market Share
Hospitals and specialty clinics accounted for the highest minimal residual disease market share. Hospitals have staff members that can help patients choose appropriate MRD tests, which is the main factor driving the market. The target illness is becoming more common; numerous testing options are available, and new tests are being developed for more precise and effective patient screening.
North America: Minimal residual disease market in North America is anticipated to expand significantly during the projection period due to increasing healthcare affordability in the United States. North America dominates the industry for minimal residual illness. The U.S. and Canada are North America's two main markets for cancer screening due to the high patient and physician awareness of the benefits of screening.
Frequently Asked Questions
By Detection Target
By Test Technique
By End User
Deep-dive Insights on Minimal Residual Disease Market by Polaris Market Research: https://polarismarketresearch.com/industry-analysis/minimal-residual-disease-market/request-for-sample
Attainment of client satisfaction being our motto, we at Polaris are happy to offer you multitude of reasons for why you should select us for your businesses.
Our commitment to our clients lies not only from the inception of our pre-on boarding discussions but also beyond the completion and delivery of our services.
We categorically offer custom-made/ tailored services for our syndicated research reports to provide you insights to meet the strategic requirements of your organization.
On lines of the industry best-practices, we offer our clients the finest in research and consulting services with the most reliable and accurate research findings.